Research programme: HIV autoimmune therapy - Peptech/Retroscreen

Drug Profile

Research programme: HIV autoimmune therapy - Peptech/Retroscreen

Latest Information Update: 20 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptech UK
  • Developer Peptech UK; Retroscreen Virology
  • Class Antibodies; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 20 Feb 2008 Discontinued - Preclinical for HIV infections treatment in United Kingdom (unspecified route)
  • 21 Aug 2001 This programme is still in active development
  • 29 Jan 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top